The European Commission has granted a conditional marketing authorisation (CMA) for the COVID‑19 vaccine Nuvaxovid, developed by Novavax, the fifth COVID-19 vaccine authorised in the EU. This authorisation follows a positive scientific recommendation based on a thorough assessment of the safety, effectiveness and quality of the vaccine by the European Medicines Agency (EMA) and is…
